Niagen Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary

Niagen Bioscience

04/08/2026 22:01

Niagen Bioscience Inc NAGE.OQ reported quarterly adjusted earnings of 1 cent​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 4 cents.  The mean expectation of six analysts for the quarter was for earnings of 2 cents per share. Wall Street expected results to range from -1 cents to 4 cents per share.
Revenue fell 4.3% to $29.79 million from a year ago; analysts expected $30.69 million. 
Niagen Bioscience Inc's reported EPS for the quarter was 1 cent​.
The company reported quarterly net income of $963 thousand.
Niagen Bioscience Inc shares had risen by 10.7% this quarter and lost 44.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 58.3% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Niagen Bioscience Inc is $11.00, about 67.9% above its last closing price of $3.53
This summary was machine generated from LSEG data August 4 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.02
0.01
Missed
Mar. 31 2026 
0.07
0.07
Met
Dec. 31 2025 
0.02
0.03
Beat
Sep. 30 2025 
0.02
0.05
Beat